Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cardiol Therapeutics (CRDL) Operating Expenses (2020 - 2026)

Cardiol Therapeutics filings provide 2 years of Operating Expenses readings, the most recent being $6.7 million for Q4 2022.

  • On a quarterly basis, Operating Expenses fell 35.52% to $6.7 million in Q4 2022 year-over-year; TTM through Dec 2022 was $31.8 million, a 0.64% decrease, with the full-year FY2025 number at $24.6 million, down 16.51% from a year prior.
  • Operating Expenses hit $6.7 million in Q4 2022 for Cardiol Therapeutics, down from $10.1 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $10.4 million in Q4 2021 to a low of $6.5 million in Q2 2021.